Seed · Biotech · Geneva, Switzerland · Founded 2016 · 10–15 employees
Antion Biosciences is a Swiss cell and gene engineering biotechnology company developing allogeneic immune cell therapies for diseases with significant unmet medical needs. Their proprietary miCAR technology enables multiplex engineering of therapeutic cells through microRNA-mediated gene silencing, allowing simultaneous modification of multiple targets in a single construct. The company has achieved significant milestones including proof-of-concept data for their lead candidate miCAR7 and a strategic collaboration with Allogene Therapeutics. They have raised $7.26M in funding and hold key patents including US Patent No. 11,649,455 for their gene silencing platform.
No open roles listed right now.